Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURGA: Viagenpumatucel-L + CPIs in NSCLC
NCT02439450Phase 2Completed
- Sponsor
- NightHawk Biosciences, Inc.
- Start
- Apr 2015
- Primary completion
- May 2021
- Modality
- Prophylactic Vaccines, Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of viagenpumatucel-L in non-small cell lung cancer (NSCLC), sponsored by NightHawk Biosciences, Inc.. Started Apr 2015; status: completed.
02
Drugs
viagenpumatucel-L
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02439450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02439450.